-

10:05:20 AM

NRXP Stock News

NRXP - NRX Pharmaceuticals Inc

08/10/22 7:45 AM

Nasdaq : NRXP

conferences

NRx Pharmaceuticals to Report Second Quarter 2022 Results on August 15, 2022

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage, biopharmaceutical company today announced that management will report second quarter

RHEA-AI

neutral

07/13/22 7:15 AM

Nasdaq : NRXP

management

NRx Pharmaceuticals Announces the Appointment of Stephen Willard, Chief Executive Officer and Director

Extensive experience in Law, Finance, and Management of Public and Private Biotechnology Companies Proven track record of creating value for shareholders National Science Board Presidential Appointee, 2018-2024 Former roles at Federal Deposit Insurance Corporation (FDIC) and E*Trade Financial

RHEA-AI

neutral

07/01/22 7:23 AM

Nasdaq : NRXP

covid-19

FDA Declines Emergency Use Authorization for ZYESAMI® (aviptadil) for subgroup of Patients with Critical COVID-19 at immediate risk of death from respiratory failure despite treatment with approved therapy, including remdesivir

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), ("NRx Pharmaceuticals"), a clinical-stage biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) has declined to

RHEA-AI

neutral

06/23/22 7:45 AM

Nasdaq : NRXP

conferences

NRx Pharmaceuticals Leaders to Present at the H.C. Wainwright & Co. 1st Annual Mental Health Conference: Neuropsychiatry, Psychedelics, and Beyond

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), ("NRx Pharmaceuticals"), a clinical-stage biopharmaceutical company, today announced its interim Chief

RHEA-AI

neutral

06/10/22 10:47 PM

Nasdaq : NRXP

NRx Pharmaceuticals Provides Update on Breakthrough Therapy Designation (BTD) Request for ZYESAMI® (aviptadil)

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP, NRx Pharmaceuticals), ("NRXP" or the "Company"), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) denied the Breakthrough Therapy designation (BTD)

RHEA-AI

neutral

06/07/22 8:02 PM

Nasdaq : NRXP

management

NRx Pharmaceuticals Appoints Seth Van Voorhees, PhD, as Chief Financial Officer and Treasurer

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, announced today that the company's Board of Directors appointed Seth Van Voorhees, Ph.D. as Chief Financial Officer and Treasurer effective June 13, 2022."Dr. Van

RHEA-AI

neutral

05/26/22 12:03 AM

Nasdaq : NRXP

covid-19

NRx Pharmaceuticals Announces Data Safety Monitoring Board (DSMB) Update on U.S. National Institutes of Health (NIH) Study of ZYESAMI® (aviptadil) in Critical COVID-19

Based on a review of nearly 75% of the target enrollment of 640 patients, most of which have reached 90 days, the Independent DSMB overseeing the ACTIV-3b (TESICO) study determined that evaluation of aviptadil should cease due to futility ZYESAMI® (aviptadil) was the sole remaining investigational

RHEA-AI

neutral

05/19/22 7:20 AM

Nasdaq : NRXP

conferences

NRx Pharmaceuticals Leaders to Present at the H.C. Wainwright & Co. Global Investment Conference

NRx Pharmaceuticals, Inc. ( Nasdaq : NRXP), a clinical-stage biopharmaceutical company, today announced its interim Chief Executive Officer, Robert Besthof, and other

RHEA-AI

neutral

05/16/22 7:12 AM

Nasdaq : NRXP

earnings

NRx Pharmaceuticals Provides Business Update and Reports First Quarter 2022 Financial Results

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP, NRx Pharmaceuticals), a clinical-stage biopharmaceutical company, today announced its financial results for the quarter ended March 31, 2022 and

RHEA-AI

neutral

05/12/22 8:17 AM

Nasdaq : NRXP

NRx Pharmaceuticals Announces Enrollment of First Patient in Phase II Study of Bipolar Depression with Sub-Acute Suicidality

NRx Pharmaceuticals, Inc., enrolled its first patient in one of two psychiatry studies being initiated this year; this first trial is studying patients with bipolar depression and sub-acute suicidality (not requiring hospitalization). NRX-101 is a patented, fixed dose combination product of

RHEA-AI

neutral

1 2 3 4 5 6 7 8 Next

NRXP Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww.nrxpharma.com
Security nameNRX Pharmaceuticals Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees2
Address2645 N Federal Hwy Ste 230
StateFlorida
CityDelray Beach
Zip33483-6111
CountryUS
Phone13107342300

About NRX Pharmaceuticals Inc

NeuroRx draws upon more than 100 years of collective drug development experience from senior executives of AstraZeneca, Eli Lilly, Novartis, Pfizer, and PPD. In addition to its work on Aviptadil, NeuroRx has been awarded Breakthrough Therapy Designation and a Special Protocol Agreement to develop NRX-101 in suicidal bipolar depression and is currently in Phase 3 trials. Its executive team is led by Prof. Jonathan C. Javitt, MD, MPH, who has served as a health advisor to four Presidential administrations and worked on paradigm-changing drug development projects for Merck, Allergan, Pharmacia, Pfizer, Novartis, and Mannkind, together with Robert Besthof, MIM, who served as the Global Vice President (Commercial) for Pfizer's Neuroscience and Pain Division. NeuroRx recently announced a plan to complete a business combination with Big Rock Partners Acquisition Corp ('BRPA'), and intends to apply for listing on the NASDAQ under the proposed symbol 'NRXP'.